Atai life sciences initiates phase 2b proof-of-concept trial of rl-007 for cognitive impairment associated with schizophrenia

New york and berlin, dec. 19, 2022 (globe newswire) -- today, atai life sciences n.v. (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its phase 2b proof-of-concept clinical trial for rl-007 for cognitive impairment associated with schizophrenia (cias), a condition for which there are currently no fda-approved treatments.
ATAI Ratings Summary
ATAI Quant Ranking